Moderna's stock soared 177% after positive late-stage trial results for its personalized mRNA cancer vaccine, developed with Merck, which reduced melanoma recurrence risk. The surge caused short sellers to lose $5.5 billion, marking a major shift for the company beyond its declining Covid vaccine business.
Moderna Surges 177% on Cancer Vaccine Trial Success
Source: Moneycontrol